Clinical Trials Logo

Dry Eye Syndromes clinical trials

View clinical trials related to Dry Eye Syndromes.

Filter by:

NCT ID: NCT03396913 Completed - Dry Eye Syndrome Clinical Trials

Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome

Start date: January 10, 2018
Phase: N/A
Study type: Interventional

The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction. The effect of IPL will be examined in a study designed as a randomized controlled trial. In the study arm, subjects will undergo 4 treatment sessions, consisting of IPL pulses immediately followed by meibomian gland expression (MGX). In the control arm, subjects will undergo the same treatments, except that the IPL pulses will be disabled. For each subject, the duration of the study will be 10 weeks, as explained in the detailed description.

NCT ID: NCT03396809 Withdrawn - Dry Eye Syndromes Clinical Trials

Punctal Plugs and Iodine Related Discomfort

Start date: July 26, 2017
Phase: N/A
Study type: Interventional

Purpose: Intravitreal injection of medications has revolutionized the treatment microvascular diseases. These diseases often require regular, life-long injections. Ensuring patient comfort is important for compliance with long-term treatments. Patients receiving regular intravitreal injections often complain of progressive dry eye related discomfort. These symptoms are likely secondary to the use of povidone iodine as an antiseptic. Investigators hypothesize that punctal plugs could reverse the progressive ocular surface discomfort induced by povidone iodine during the post-procedural state.

NCT ID: NCT03395431 Not yet recruiting - Dry Eye Syndromes Clinical Trials

Fingerprick Autologous Blood (FAB) in Severe Dry Eye Disease (DED)

FAB
Start date: February 2018
Phase: N/A
Study type: Interventional

Dry eye disease (DED) is an umbrella term encompassing a range of diseases estimated to affect 14% of all adults aged 48 to 91. If left untreated, DED can lead to severe reduction in the quality of life of the sufferer. It can also cause loss of vision, pain in response to light, painful recurring stabbing sensations, and the feeling of grit in the affected eye(s). No curative agents for DED exist. Available conventional treatment options for DED such as artificial tears often only alleviate symptoms, have limited effectiveness, and in most cases patients may fail to respond; although the exact rate of treatment failure is unavailable in the published literature. Crudely, human tears with its vast constituents is essentially filtered blood and as such is an obvious source for a "tear mimic" containing the substances of tears. Blood, and several blood derived products, including autologous serum, have been studied as tear substitute candidates. This study proposes to test the use of finger prick autologous blood (FAB) technique in which whole blood is applied to the eye from a cleaned finger.

NCT ID: NCT03380624 Completed - Dry Eye Syndromes Clinical Trials

Tear Lipid Layer Thickness With Emollient Eye Drops

Start date: March 1, 2017
Phase: Phase 4
Study type: Interventional

Crossover comparison of lipid layer thickness with two artificial tear formulations

NCT ID: NCT03368404 Completed - Dry Eye Clinical Trials

A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

RESTA
Start date: November 9, 2017
Phase: N/A
Study type: Interventional

This is a multicenter, randomized, parallel group, investigator-masked, non-inferiority study. Approximately 84 subjects will be randomized in a 1:1 ratio.The primary objectives of this investigation are to show that the performance of CBL-102 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-102 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day. The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye at Visit 4 (Day 28 ± 3 days) in ocular surface fluorescein staining score.

NCT ID: NCT03364322 Completed - Dry Eye Syndrome Clinical Trials

Influencing Factors on Dry Eye Syndrome and Ocular Surface Disease

Start date: June 1, 2016
Phase: N/A
Study type: Observational

Dry eye syndrome and ocular surface disease are very important ophthalmologic diseases. It is known that various inducers are involved. However, it is still necessary to study how influencing factors are related to dry eye syndrome and ocular surface disease and how treatment for dry eye syndrome and ocular surface disease is helpful.

NCT ID: NCT03358979 Recruiting - Dry Eye Syndromes Clinical Trials

Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE)

ALTESSE
Start date: December 14, 2017
Phase:
Study type: Observational

Modifications of cell surface markers (including EMMPRIN) were observed in conjunctival epithelial cells during dry eye syndrome ; this study aims to describe the modifications of the repartition of these cell surface markers before and after initiation of a treatment.

NCT ID: NCT03345381 Not yet recruiting - Depression Clinical Trials

Impact of Breathing Exercises and Meditation on Quality of Life in Dry Eye Disease Patients: A Pilot Study

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

People staring at computer screens for long hours, blinking less frequently, or having long-term contact lens wear are prone to dry eye disease (DED). DED is a multifactorial disease accompanied by inflammation of the ocular surface. Further, DED may degrade vision and is associated with depression and have an adverse impact on patient's quality of life. Sudarshan Kriya Yoga (SKY) incorporates standardized collection of breathing techniques followed by Automatic Self Transcending Meditation (ASTM) may help reduce stress, depression, and anxiety, enhance quality of life in patients diagnosed with DED. Thus, the investigators will be studying the effect of SKY plus ASTM on quality of life of DED patients. The investigators plan to conduct a single-center pilot RCT. Patients with DED will be randomized to SKY followed by ASTM plus Usual care (UC) or UC alone to assess changes in health-related quality of life (HRQOL). HRQOL is a vital construct focusing on impact of health on quality of life. Along with HRQOL the investigators will measure changes in extent of depression and anxiety. Additionally, majority of current ophthalmic literature describes changes in clinical variables whilst lacking information on HRQOL. Thus, there is a high necessity to assess if there is an association between HRQOL and routinely measured clinical data. Through this study the investigators shall attempt to correlate HRQOL with clinical data.

NCT ID: NCT03334539 Completed - Dry Eye Clinical Trials

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes

VELOS-1
Start date: November 5, 2017
Phase: Phase 2
Study type: Interventional

The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

NCT ID: NCT03333057 Completed - Clinical trials for Dry Eye Disease (DED)

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Start date: January 3, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).